Acrivon Therapeutics, Common Stock Performance
| ACRV Stock | 7.16 0.61 9.31% |
The firm shows a Beta (market volatility) of 1.78, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acrivon Therapeutics, will likely underperform. At this point, Acrivon Therapeutics, has a negative expected return of -0.32%. Please make sure to confirm Acrivon Therapeutics,'s total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Acrivon Therapeutics, performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in December 2024. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 7.8 | Five Day Return 10.66 | Year To Date Return 40.92 | Ten Year Return (57.57) | All Time Return (57.57) |
1 | Acrivon Therapeutics to Present at the Cantor Global Healthcare Conference | 09/10/2024 |
2 | Acrivon Therapeutics Upgraded at LADENBURG THALMSH SH | 09/20/2024 |
3 | Disposition of 284 shares by Miller Mary of Acrivon Therapeutics, at 6.98 subject to Rule 16b-3 | 10/01/2024 |
4 | Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635 | 10/16/2024 |
5 | Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conf... | 10/17/2024 |
6 | Disposition of 490 shares by Blume-jensen Peter of Acrivon Therapeutics, at 7.92 subject to Rule 16b-3 | 11/14/2024 |
| Begin Period Cash Flow | 29.9 M |
Acrivon |
Acrivon Therapeutics, Relative Risk vs. Return Landscape
If you would invest 927.00 in Acrivon Therapeutics, Common on August 28, 2024 and sell it today you would lose (211.00) from holding Acrivon Therapeutics, Common or give up 22.76% of portfolio value over 90 days. Acrivon Therapeutics, Common is currently does not generate positive expected returns and assumes 4.2811% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Acrivon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acrivon Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acrivon Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acrivon Therapeutics, Common, and traders can use it to determine the average amount a Acrivon Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0743
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ACRV |
Estimated Market Risk
| 4.28 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.32 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Acrivon Therapeutics, is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acrivon Therapeutics, by adding Acrivon Therapeutics, to a well-diversified portfolio.
Acrivon Therapeutics, Fundamentals Growth
Acrivon Stock prices reflect investors' perceptions of the future prospects and financial health of Acrivon Therapeutics,, and Acrivon Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acrivon Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 20.5 M | ||||
| Shares Outstanding | 31.14 M | ||||
| Price To Book | 1.04 X | ||||
| EBITDA | (59.85 M) | ||||
| Net Income | (60.39 M) | ||||
| Total Debt | 4.64 M | ||||
| Book Value Per Share | 5.38 X | ||||
| Cash Flow From Operations | (42.64 M) | ||||
| Earnings Per Share | (2.66) X | ||||
| Market Capitalization | 203.94 M | ||||
| Total Asset | 138.26 M | ||||
| Retained Earnings | (116.42 M) | ||||
| Working Capital | 116.39 M | ||||
About Acrivon Therapeutics, Performance
Evaluating Acrivon Therapeutics,'s performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Acrivon Therapeutics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Acrivon Therapeutics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.50) | (0.47) |
Things to note about Acrivon Therapeutics, performance evaluation
Checking the ongoing alerts about Acrivon Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acrivon Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acrivon Therapeutics, generated a negative expected return over the last 90 days | |
| Acrivon Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics, generates negative cash flow from operations | |
| Acrivon Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from investing.com: Disposition of 490 shares by Blume-jensen Peter of Acrivon Therapeutics, at 7.92 subject to Rule 16b-3 |
- Analyzing Acrivon Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acrivon Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Acrivon Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acrivon Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acrivon Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acrivon Therapeutics,'s stock. These opinions can provide insight into Acrivon Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.